NASDAQ:DOXAmdocs Stock Price, Forecast & News

Amdocs' stock was trading at $61.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DOX stock has decreased by 0.5% and is now trading at $61.12.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amdocs in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amdocs.

Amdocs is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Amdocs.

Amdocs Limited (NASDAQ:DOX) posted its quarterly earnings results on Wednesday, August, 5th. The technology company reported $1.07 EPS for the quarter, topping analysts' consensus estimates of $1.05 by $0.02. Amdocs had a net margin of 11.71% and a return on equity of 15.30%.
View Amdocs' earnings history.

Amdocs declared a quarterly dividend on Wednesday, August 5th. Investors of record on Wednesday, September 30th will be given a dividend of $0.327 per share on Friday, October 23rd. This represents a $1.31 dividend on an annualized basis and a dividend yield of 2.14%. The ex-dividend date of this dividend is Tuesday, September 29th.
View Amdocs' dividend history.

Amdocs issued an update on its fourth quarter earnings guidance on Wednesday, August, 5th. The company provided earnings per share (EPS) guidance of $1.16-1.22 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.16. The company issued revenue guidance of $1.015-1.055 billion, compared to the consensus revenue estimate of $1.03 billion.

5 analysts have issued 1 year target prices for Amdocs' stock. Their forecasts range from $72.00 to $76.00. On average, they anticipate Amdocs' share price to reach $74.40 in the next year. This suggests a possible upside of 21.7% from the stock's current price.
View analysts' price targets for Amdocs.

Media headlines about DOX stock have trended extremely negative this week, InfoTrie reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amdocs earned a news sentiment score of -4.1 on InfoTrie's scale. They also assigned news articles about the technology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term.
View the latest news about Amdocs.

Amdocs saw a decline in short interest during the month of July. As of July 31st, there was short interest totaling 2,590,000 shares, a decline of 9.1% from the July 15th total of 2,850,000 shares. Based on an average trading volume of 890,300 shares, the short-interest ratio is currently 2.9 days. Approximately 1.9% of the company's shares are short sold.
View Amdocs' Short Interest.

Some companies that are related to Amdocs include Accenture (ACN), IBM (IBM), Cognizant Technology Solutions (CTSH), EPAM Systems (EPAM), Leidos (LDOS), Gartner (IT), Booz Allen Hamilton (BAH), Caci International (CACI), Mantech International (MANT), Teradata (TDC), Virtusa (VRTU), Unisys (UIS), Forrester Research (FORR), The Hackett Group (HCKT) and Servicesource International (SREV).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amdocs investors own include AT&T (T), AbbVie (ABBV), Comcast (CMCSA), Home Depot (HD), IBM (IBM), Pfizer (PFE), Exxon Mobil (XOM), Cisco Systems (CSCO), Walt Disney (DIS) and Johnson & Johnson (JNJ).

Amdocs trades on the NASDAQ under the ticker symbol "DOX."

Amdocs' stock is owned by many different institutional and retail investors. Top institutional investors include LSV Asset Management (3.80%), Robeco Institutional Asset Management B.V. (1.32%), Principal Financial Group Inc. (0.90%), First Trust Advisors LP (0.82%), Wedge Capital Management L L P NC (0.63%) and AJO LP (0.62%).

DOX stock was sold by a variety of institutional investors in the last quarter, including Cooke & Bieler LP, Goldman Sachs Group Inc., Anchor Capital Advisors LLC, Bessemer Group Inc., Denali Advisors LLC, New York State Common Retirement Fund, Russell Investments Group Ltd., and Robeco Institutional Asset Management B.V..

DOX stock was purchased by a variety of institutional investors in the last quarter, including LSV Asset Management, Wedge Capital Management L L P NC, Prudential Financial Inc., CWM LLC, Principal Financial Group Inc., AJO LP, UNIVEST FINANCIAL Corp, and Exane Asset Management.

Shares of DOX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DOX stock can currently be purchased for approximately $61.12.

Amdocs has a market capitalization of $8.24 billion and generates $4.09 billion in revenue each year. The technology company earns $479.45 million in net income (profit) each year or $4.07 on an earnings per share basis. Amdocs employs 24,516 workers across the globe.

The official website for Amdocs is www.amdocs.com.

Amdocs' mailing address is 1390 Timberlake Manor Parkway, Chesterfield MO, 63017. The technology company can be reached via phone at 1 314 212 7000 or via email at [email protected]